이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Avadel Pharmaceuticals 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Greg Divis
최고 경영자
US$985.2k
총 보상
CEO 급여 비율 | 60.9% |
CEO 임기 | 5.7yrs |
CEO 소유권 | n/a |
경영진 평균 재임 기간 | 4.8yrs |
이사회 평균 재임 기간 | 6.2yrs |
최근 관리 업데이트
Recent updates
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$106m |
Mar 31 2024 | n/a | n/a | -US$157m |
Dec 31 2023 | US$985k | US$600k | -US$160m |
Sep 30 2023 | n/a | n/a | -US$159m |
Jun 30 2023 | n/a | n/a | -US$143m |
Mar 31 2023 | n/a | n/a | -US$142m |
Dec 31 2022 | US$754k | US$561k | -US$137m |
Sep 30 2022 | n/a | n/a | -US$132m |
Jun 30 2022 | n/a | n/a | -US$134m |
Mar 31 2022 | n/a | n/a | -US$90m |
Dec 31 2021 | US$3m | US$545k | -US$77m |
Sep 30 2021 | n/a | n/a | -US$66m |
Jun 30 2021 | n/a | n/a | -US$56m |
Mar 31 2021 | n/a | n/a | -US$6m |
Dec 31 2020 | US$3m | US$520k | US$7m |
Sep 30 2020 | n/a | n/a | US$16m |
Jun 30 2020 | n/a | n/a | US$18m |
Mar 31 2020 | n/a | n/a | -US$21m |
Dec 31 2019 | US$1m | US$472k | -US$33m |
Sep 30 2019 | n/a | n/a | -US$94m |
Jun 30 2019 | n/a | n/a | -US$101m |
Mar 31 2019 | n/a | n/a | -US$96m |
Dec 31 2018 | US$685k | US$417k | -US$95m |
Sep 30 2018 | n/a | n/a | -US$40m |
Jun 30 2018 | n/a | n/a | -US$2m |
Mar 31 2018 | n/a | n/a | US$30m |
Dec 31 2017 | US$1m | US$375k | US$68m |
보상 대 시장: Greg 의 총 보상 ($USD 985.20K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.67M ).
보상과 수익: 회사가 수익성이 없는 동안 Greg 의 보상이 증가했습니다.
CEO
Greg Divis (57 yo)
5.7yrs
테뉴어
US$985,200
보상
Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
CEO & Director | 5.7yrs | US$985.20k | 데이터 없음 | |
Senior VP | 4.8yrs | US$663.14k | 0.084% $ 1.0m | |
Chief Commercial Officer | 3.6yrs | US$770.95k | 0% $ 0 | |
General Counsel & Company Secretary | 4yrs | 데이터 없음 | 0.0091% $ 112.2k | |
VP of Corporate and Business Development | 9.2yrs | 데이터 없음 | 0.17% $ 2.0m | |
Vice President of Sales | 8.1yrs | 데이터 없음 | 데이터 없음 | |
Vice President of People & Culture | 3.3yrs | 데이터 없음 | 데이터 없음 | |
Consultant | 5.4yrs | US$982.54k | 데이터 없음 | |
Senior Vice President of Technical Operations | 4.8yrs | 데이터 없음 | 데이터 없음 | |
Senior Vice President of Medical & Clinical Affairs | no data | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: AVDL 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
CEO & Director | 5.3yrs | US$985.20k | 데이터 없음 | |
Member of Scientific Advisory Board | 19.7yrs | 데이터 없음 | 데이터 없음 | |
Independent Director | 4.8yrs | US$449.84k | 0.070% $ 854.6k | |
Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
Independent Director | 7.3yrs | US$459.84k | 0.086% $ 1.1m | |
Member of Scientific Advisory Board | 19.7yrs | 데이터 없음 | 데이터 없음 | |
Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
Independent Director | 5.8yrs | US$452.34k | 0.17% $ 2.1m | |
Chairman of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
Independent Non-Executive Chairman of the Board | 6.2yrs | US$482.34k | 0.13% $ 1.6m | |
Independent Director | 6.2yrs | US$452.34k | 0.054% $ 668.1k |
6.2yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 이사회: AVDL 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.